Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

The prostratron: microwaves for benign prostatic hyperplasia

Article Abstract:

Transurethral microwave thermotherapy (TUMT) with the Prostatron has been approved as an alternative treatment to surgery for symptoms of benign prostatic hyperplasia (BPH). BPH is the cause of severe urinary obstruction. The device uses microwave energy to heat the prostate, partially destroying obstructive tissue. The one-hour session only requires the application of analgesic jelly but may not take effect until months later. Compared to surgery, TUMT produced less favorable peak urinary flow rates. Urinary retention may occur in about one third of all cases after TUMT, requiring an indwelling catheter for up to one month. Urinary tract infections, blood in the urine, and sexual dysfunctions after TUMT are reportedly rare.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1996
Urine, Urinary retention, Hyperthermia treatment systems (Medical care), Hyperthermia treatment equipment

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Tamsulosin for benign prostatic hyperplasia

Article Abstract:

Tamsulosin, also called Flomax, may be as effective as other alpha1-blockers available for treatment of benign prostatic hyperplasia (BPH). Tamsulosin was shown to be more effective than placebos in increasing urine flow rates in men with BPH. Maximum effectiveness occurred within two weeks, compared to treatment with the enzyme Finasteride, which can take up to twelve months. In some studies, side effects due to lowered blood pressure were reported less often than with other alpha1-blockers, like terazosin or doxazosin. No direct comparisons are available between tamsulosin and other drugs used for the treatment of BPH.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1997
Product/Service Evaluation, Flomax (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Saw palmetto for benign prostatic hyperplasia

Article Abstract:

Saw palmetto may reduce the symptoms of benign prostate enlargement. This herbal supplement grows as a small palm tree and an extract of the berries has been studied in the treatment of prostate enlargement. Eighteen clinical trials of several saw palmetto products showed that they reduced symptoms, but many men also respond to a placebo. In addition, the exact composition of the products is not always known. Further research is needed before this herb can be recommended for the treatment of prostate enlargement.

Publisher: Medical Letter, Inc.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1999
Health aspects, Care and treatment, Prostate diseases, Prostatic diseases, Saw-palmetto, Saw palmetto

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Evaluation, Prostate, Prostatic hyperplasia
Similar abstracts:
  • Abstracts: The consultant nurse: a model for advanced practice. Pulmonary embolus. Evaluation of primary nursing in a nursing development unit
  • Abstracts: Increased placental progesterone may cause decreased placental prostacyclin production in preeclampsia. Preeclampsia: the effects of serum on endothelial cell prostacyclin, endothelin, and cell membrane integrity
  • Abstracts: Torsades de pointes occurring in association with terfenadine use. Coprescribing and Codispensing of Cisapride and Contraindicated Drugs
  • Abstracts: Collagen metabolism in premature rupture of amniotic membranes. Increased concentration of pro-matrix metalloproteinase 9 in term fetal membranes overlying the cervix before labor: implications for membrane remodeling and rupture
  • Abstracts: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.